JP2010526076A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526076A5
JP2010526076A5 JP2010506507A JP2010506507A JP2010526076A5 JP 2010526076 A5 JP2010526076 A5 JP 2010526076A5 JP 2010506507 A JP2010506507 A JP 2010506507A JP 2010506507 A JP2010506507 A JP 2010506507A JP 2010526076 A5 JP2010526076 A5 JP 2010526076A5
Authority
JP
Japan
Prior art keywords
crig
antibody
composition
fragment
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010506507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526076A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/061513 external-priority patent/WO2008137338A1/en
Publication of JP2010526076A publication Critical patent/JP2010526076A/ja
Publication of JP2010526076A5 publication Critical patent/JP2010526076A5/ja
Pending legal-status Critical Current

Links

JP2010506507A 2007-05-01 2008-04-25 CRIgアンタゴニスト Pending JP2010526076A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91534007P 2007-05-01 2007-05-01
PCT/US2008/061513 WO2008137338A1 (en) 2007-05-01 2008-04-25 CRIg ANTAGONISTS

Publications (2)

Publication Number Publication Date
JP2010526076A JP2010526076A (ja) 2010-07-29
JP2010526076A5 true JP2010526076A5 (enExample) 2012-05-31

Family

ID=39645433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506507A Pending JP2010526076A (ja) 2007-05-01 2008-04-25 CRIgアンタゴニスト

Country Status (16)

Country Link
US (1) US20090162356A1 (enExample)
EP (1) EP2152749A1 (enExample)
JP (1) JP2010526076A (enExample)
KR (1) KR20100018523A (enExample)
CN (1) CN101675078A (enExample)
AR (1) AR066375A1 (enExample)
AU (1) AU2008247958A1 (enExample)
BR (1) BRPI0810926A2 (enExample)
CA (1) CA2682835A1 (enExample)
CL (1) CL2008001238A1 (enExample)
IL (1) IL201165A0 (enExample)
MX (1) MX2009011407A (enExample)
PE (1) PE20090239A1 (enExample)
RU (1) RU2009144280A (enExample)
WO (1) WO2008137338A1 (enExample)
ZA (1) ZA200906812B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
LT2280996T (lt) * 2008-05-06 2016-12-12 Genentech, Inc. Subrendusio giminingumo crig variantai
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105924515B (zh) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10752689B2 (en) * 2017-06-26 2020-08-25 Bio-Techne Corporation Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using
KR102857892B1 (ko) * 2018-09-28 2025-09-10 주식회사 유틸렉스 항-인간 vsig4 항체 및 이의 용도
WO2020236626A1 (en) * 2019-05-17 2020-11-26 Herzlinger George A Methods and systems for treating microbial disease
MX2022002672A (es) * 2019-09-04 2022-06-16 Y Biologics Inc Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
KR20230156727A (ko) 2021-03-03 2023-11-14 피에르 파브르 메디카먼트 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders

Similar Documents

Publication Publication Date Title
JP2010526076A5 (enExample)
RU2009144280A (ru) АНТАГОНИСТЫ CRIg
JP2011505867A5 (enExample)
JP2018506966A5 (enExample)
JP2018035138A5 (enExample)
JP2018535650A5 (enExample)
JP2018500014A5 (enExample)
JP2018521638A5 (enExample)
JP2017531642A5 (enExample)
JP2018502840A5 (enExample)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2011527902A5 (enExample)
AR109882A1 (es) Anticuerpos monoclonales neutralizantes anti-tl1a
JP2012254092A5 (enExample)
CA2952055A1 (en) Monoclonal antibodies for ebola and marburg viruses
JP2011527899A5 (enExample)
FI2897981T3 (fi) Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä
JP2017534577A5 (enExample)
JP2018520334A5 (enExample)
JP2006020633A (ja) 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
JP2015503909A5 (enExample)
JPWO2019246514A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2017507657A5 (enExample)
JP2020533965A5 (enExample)